The pCPA is thrilled to expand its negotiation pathway options with the launch of the Early Negotiation Process (ENP) and the Targeted Negotiation Process (TNP). These expedited negotiation pathways are designed to accelerate negotiation timelines.
Reflecting on 2025, a year of big progress and big steps for the pCPA
We understand the importance of timely public drug coverage for Canadian patients. That’s why we’re introducing new and refreshed negotiation processes. Full details of our Early Negotiation Process (ENP) and our Targeted Negotiation Process (TNP) are now available for review.
The pCPA teams are currently working on new approaches to our negotiation processes with the goal of supporting timely public drug coverage for Canadian patients.
The pCPA’s Board of Directors is pleased to announce the release of our 2024–25 impact report.
After his first 100 days as chief executive officer of the pCPA, Mauro Chies shares his thoughts on the organization, his experiences and what he sees for the future of the pCPA.
New data shows negotiation timelines for oncology drugs dropped to 5 months in 2024, their lowest level ever.
We are thrilled to announce the launch of a refreshed brand identity for the pCPA, marking a significant milestone in our evolution toward a more modern organization.
The pan-Canadian Pharmaceutical Alliance’s (pCPA) Board of Directors is pleased to announce the appointment of Mauro Chies as chief executive officer (CEO), effective February 10, 2025.